AnalystsCorinne JohnsonCorinne Johnson's Stock Forecasts
AnalystsCorinne Johnson
Sectors:
Analyst Ranking
Top 33%
#1705 out of 5290 analysts
Average Return
+9.51%
Win Rate
50%8 out of 16
Risk vs Reward
Poor
Good
Corinne Johnson's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Amylyx Pharmaceuticals IncAMLX | +93.64% | $7.39 | $14.31 | 2025-07-09 - 2026-06-04 | Strong Buy |
Syndax Pharmaceuticals IncSNDX | +83.50% | $9.82 | $18.02 | 2025-07-09 - 2026-06-04 | Strong Buy |
Arrivent Biopharma IncAVBP | +50.20% | $22.03 | $33.09 | 2025-07-09 - 2026-06-04 | Strong Buy |
Arrivent Biopharma IncAVBP | +31.41% | $20.63 | $27.11 | 2024-02-19 - 2025-02-19 | Strong Buy |
Neurocrine Biosciences IncNBIX | +24.04% | $134.92 | $167.35 | 2025-07-09 - 2026-06-04 | Strong Buy |
Corinne Johnson Analyst Color
Get additional color on Corinne Johnson's coverage of popular stocks
Corinne Johnson's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Neurocrine Biosciences IncNBIX | 2 | Strong Buy | $213.00 | +27.28% | Reinstates | 3 days ago |
Immunovant IncIMVT | 3 | Hold | $32.00 | -2.05% | Maintains | 2 months ago |
Syndax Pharmaceuticals IncSNDX | 3 | Strong Buy | $34.00 | +88.68% | Maintains | 2 months ago |
Tg Therapeutics IncTGTX | 1 | Hold | $39.00 | -3.85% | Maintains | 5 months ago |
Mbx Biosciences IncMBX | 1 | Strong Sell | $18.00 | -41.77% | Initiates Coverage On | 6 months ago |
Amylyx Pharmaceuticals IncAMLX | 2 | Strong Buy | $20.00 | +39.76% | Maintains | 9 months ago |
Avidity Biosciences IncRNAM | 2 | Strong Buy | $55.00 | +272.88% | Reinstates | a year ago |
Arrivent Biopharma IncAVBP | 3 | Strong Buy | $33.00 | -0.27% | Reinstates | a year ago |
Cg Oncology IncCGON | 3 | Strong Buy | $50.00 | N/A | Upgrades | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.